1) Global health diplomacy is needed to tackle AIDS because no single country has enough resources and international cooperation is required, especially for issues like migrant populations.
2) Key international organizations that work on AIDS include UNAIDS, PEPFAR, GFATM, WHO, and various UN agencies. They focus on increasing access to testing, treatment, and prevention programs.
3) COVID-19 has disrupted progress on AIDS goals by reducing access to testing, treatment, and ARV drugs. New global strategies are needed to address this challenge.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Annette Verster, WHO
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Annette Verster, WHO
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
This interactive webinar is part of the world tour series designed by the World Health Organization's Patients for Patient Safety (PFPS) Global Network and hosted by Patients for Patient Safety Canada, the patient-led program of the Canadian Patient Safety Institute, a WHO Collaborating Centre on Patient Safety and Patient Engagement.
NATIONAL AIDS CONTROL PROGRAM
1992- - NACP 1 launched to show down the spread of HIV infection
- national AIDS control board constituted
- NACO setup
1999- - NACP 2 begins focusing on behaviour change , increased decentralization and NGO involvement.
- state AIDS control societies developed .
2002- - national AIDS control policy adopted.
- national blood policy adopted.
2004- - antiretroviral treatment initiated .
2006- - national council on AIDS constituted under chairmanship of prime minister.
- national policy on paediatric ART formulated.
2007- - NACP 3 launched for years (2007-2012)
2012- - NACP 4 launched for next 5 years
The mission of the Sexually Transmitted Diseases (STD) Control Program is to reduce the occurrence of STDs through disease surveillance, case and outbreak investigation, screening, preventive therapy, outreach, diagnosis, case management, and education.
NATIONAL AIDS CONTROL PROGRAMME(NACP) PPT BY KRITIKA.pptxKritikaDhawan9
Acquired immunodeficiency syndrome (AIDS) is a chronic , potentially life, threating condition caused by the human immunodeficiency virus(HIV), a human retrovirus . By, damaging your immune system , HIV interferes with your body's ability to fight infection and disease.
HIV uses the machinery of the CD4 cells to multiply and spread throughout the body .
This interactive webinar is part of the world tour series designed by the World Health Organization's Patients for Patient Safety (PFPS) Global Network and hosted by Patients for Patient Safety Canada, the patient-led program of the Canadian Patient Safety Institute, a WHO Collaborating Centre on Patient Safety and Patient Engagement.
NATIONAL AIDS CONTROL PROGRAM
1992- - NACP 1 launched to show down the spread of HIV infection
- national AIDS control board constituted
- NACO setup
1999- - NACP 2 begins focusing on behaviour change , increased decentralization and NGO involvement.
- state AIDS control societies developed .
2002- - national AIDS control policy adopted.
- national blood policy adopted.
2004- - antiretroviral treatment initiated .
2006- - national council on AIDS constituted under chairmanship of prime minister.
- national policy on paediatric ART formulated.
2007- - NACP 3 launched for years (2007-2012)
2012- - NACP 4 launched for next 5 years
The mission of the Sexually Transmitted Diseases (STD) Control Program is to reduce the occurrence of STDs through disease surveillance, case and outbreak investigation, screening, preventive therapy, outreach, diagnosis, case management, and education.
NATIONAL AIDS CONTROL PROGRAMME(NACP) PPT BY KRITIKA.pptxKritikaDhawan9
Acquired immunodeficiency syndrome (AIDS) is a chronic , potentially life, threating condition caused by the human immunodeficiency virus(HIV), a human retrovirus . By, damaging your immune system , HIV interferes with your body's ability to fight infection and disease.
HIV uses the machinery of the CD4 cells to multiply and spread throughout the body .
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Struggling with intense fears that disrupt your life? At Renew Life Hypnosis, we offer specialized hypnosis to overcome fear. Phobias are exaggerated fears, often stemming from past traumas or learned behaviors. Hypnotherapy addresses these deep-seated fears by accessing the subconscious mind, helping you change your reactions to phobic triggers. Our expert therapists guide you into a state of deep relaxation, allowing you to transform your responses and reduce anxiety. Experience increased confidence and freedom from phobias with our personalized approach. Ready to live a fear-free life? Visit us at Renew Life Hypnosis..
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
3. • New infections-1.7 million
• Old cases- 38 million
• Died- 33 million so far
• India has 3 rd position in AIDS epidemic.
4. Why we need GHD in AIDS?
• No one country can alone prevent AIDS.
• For example, In case of migrants, combined action of both
countries are needed.
• Every country will not have the enough resources to tackle
the problem.
• International relations provide them better funding,
technology, knowledge.
• Brazil was able to provide reduction in cost of ARV drugs
due to the TRIPS agreement. It provides the right to
compulsory license for ARV medication in time of health
crisis.
• TRIPS offers patent rules with consideration to public
health.
5. What we need to do?
• National and international links and communication.
• Increasing community leadership at national and international
level.
• Attention to political and cultural needs in global health
programs.
• Eg: Iraq, Afganisthan, South Sudan-the design, delivery and
development of health services based on peace-keeping,
international relations, mutual support.
• Negotiations to reduce political and military conflicts between
countries
• Encourage research in global level and share the knowledge.
• International health programs based on humanist concept.
• Interdisciplinary approach.
6. International organizations for AIDS
1.PEPFAR
• US President’s Emergency Plan For AIDS Relief.
• Largest commitment for a single disease- 50 countries
• Managed by office of US global AIDS coordinator and
health diplomacy.
• Funding for treatment, prevention and research.
• Provide innovative solutions for the need of people
through data driven policies- control HIV by 2020.
• Focus on vulnerable communities like orphans and
children.
7. 2. GFATM
• Global Fund to Fight AIDS, TB, Malaria.
• Financing and partnership organization-to control
AIDS, TB, Malaria.
• World’s largest financiers for AIDS, TB and Malaria.
• Finance for 18.9 million people for ARV drugs.
• Act as a financing body, while programs are
implemented by the country, NGOs, private sector,
people with HIV.
• Since 2006 in India.
8. 3. UNAIDS
• It focus to end AIDS by 2030 as part of SDG.
• People with HIV infections are involved in decision
making, designing, delivering and monitoring AIDS
response.
• It provides direction, advocacy, technical support to
connect leadership and deliver services.
• It leads the world’s most extensive data collection on HIV.
• Fast-track strategy (2014)- 90-90-90 goals- 90% of the
people with HIV know their status, 90% of people who
know the status will use ARV, 90% of people using ARV
will have viral suppression by 2020.
9. • Created new 2025 target for better prevention-
1. 10s- better environment-less than 10% of the countries
have policies and laws that deny justice for
marginalized, less than 10% of people face stigma,
discrimination, gender inequality and violence.
2. 95s- 95% of testing, treatment, viral suppression. 95%
access to sexual and reproductive health, 95% coverage
for prevention of mother to child transmission.
3. Service integration-90% of people with HIV and risk will
be linked to essential health services.
• Since 1999 in India.
10. 4. WHO
• It helps to respond to HIV.
• It increases the coverage for ARV treatment, disease
prevention to new born.
• It is the cosponsor of UNAIDS.
• Joint with UNICEF to prevent transmission of HIV from mother
to new born.
• Global health sector strategy on HIV/AIDS 2016-21- renew
political commitment, resource development, innovations in
technology. Against stigma and discrimination.
11. 5.UN AGENCIES
UNFPA
• Increase the access of HIV related services, It integrates HIV response to sexual
and Reproductive health services.
ILO
• Code of practice in work place- non-discrimination, screening, confidentiality,
prevention, care and support.
• Focusing on migrants- none of the migrants should be discriminated based on
their place of origin and HIV status.
UNODC
• UN office in drugs and crime-cosponsor of UNAIDS.
• Focus on 90% of people who injects drugs and 90% people in prisons to
provide access to HIV prevention services.
UNICEF
• Preventing transmission of HIV from Mother to child.
• Also focusing on children and adolescents.
12. COVID AND AIDS GHD
• COVID-19 has made disruption in achieving
the goals of these GHD practices.
• It reduced testing and treatment.
• People with unknown status can spread the
disease.
• Difficulties in accessing ARV drugs.
• New strategies is needed in global level for
tackling the disease. Eg: based on social media
13. REFERENCES
• Gómez, E., 2012. Understanding Brazilian global health diplomacy: Social health
movements, institutional infiltration, and the geopolitics of accessing HIV/AIDS
medication. Global Health Govern, 6(1).
• Wogart, J.P., Calcagnotto, G., Hein, W. and Von Soest, C., 2008. AIDS, access to
medicines, and the different roles of the Brazilian and South African governments
in global health governance (No. 86). GIGA Working Papers.
• Kevany S. Global Health Diplomacy, "San Francisco Values," and HIV/AIDS: From
the Local to the Global. Ann Glob Health. 2015 Sep-Oct;81(5):611-7. doi:
10.1016/j.aogh.2015.12.004. PMID: 27036717.
• https://www.hiv.gov.in
• https://www.who.int
• https://www.unicef.org